Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Jerome T, Mettetal"'
Autor:
Christina Vasalou, Theresa A. Proia, Laura Kazlauskas, Anna Przybyla, Matthew Sung, Srinivas Mamidi, Kim Maratea, Matthew Griffin, Rebecca Sargeant, Jelena Urosevic, Anton I. Rosenbaum, Jiaqi Yuan, Krishna C. Aluri, Diane Ramsden, Niresh Hariparsad, Rhys D.O. Jones, Jerome T. Mettetal
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 6, Pp 994-1005 (2024)
Abstract Trastuzumab deruxtecan (T‐DXd; DS‐8201; ENHERTU®) is a human epithelial growth factor receptor 2 (HER2)‐directed antibody drug conjugate (ADC) with demonstrated antitumor activity against a range of tumor types. Aiming to understand t
Externí odkaz:
https://doaj.org/article/9ec3eba9f35b4e748d121b8d38437da3
Autor:
Matthias Pfeifer, Jonathan S. Brammeld, Stacey Price, James Pilling, Deepa Bhavsar, Anca Farcas, Jessica Bateson, Anjana Sundarrajan, Ricardo J. Miragaia, Nin Guan, Stephanie Arnold, Laiba Tariq, Michael Grondine, Sarah Talbot, Maria Lisa Guerriero, Daniel J. O’Neill, Jamie Young, Carlos Company, Shanade Dunn, Hannah Thorpe, Matthew J. Martin, Kimberly Maratea, Daniel Barrell, Miika Ahdesmaki, Jerome T. Mettetal, Functional Genomics Centre, James Brownell, Ultan McDermott
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-16 (2024)
Abstract Most lung cancer patients with metastatic cancer eventually relapse with drug-resistant disease following treatment and EGFR mutant lung cancer is no exception. Genome-wide CRISPR screens, to either knock out or overexpress all protein-codin
Externí odkaz:
https://doaj.org/article/ed715ab2efbd4a99b27d7f1bbae4d95d
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 9, Pp 498-508 (2020)
Stability analysis, often overlooked in pharmacometrics, is essential to explore dynamical systems. The model developed by Friberg et al.1 to describe drug‐induced hematotoxicity is widely used to support decisions across drug development, and para
Externí odkaz:
https://doaj.org/article/291292eba3d0466999335eab1b98cfea
Autor:
Chiara Fornari, Lenka Oplustil O'Connor, Carmen Pin, Aaron Smith, James W.T. Yates, S.Y. Amy Cheung, Duncan I. Jodrell, Jerome T. Mettetal, Teresa A. Collins
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 858-868 (2019)
Haematological toxicity associated with cancer therapeutics is monitored by changes in blood cell count, and their primary effect is on proliferative progenitors in the bone marrow. Using observations in rat bone marrow and blood, we characterize a m
Externí odkaz:
https://doaj.org/article/5848ecf4800c4426a41a4c13b85eb890
Publikováno v:
Cancer Research. 83:3456-3456
Background: Combination therapies are frequently employed as part of cancer treatment, often with the goal of preventing or slowing the development of drug resistance. Empirically developed combination therapies have had remarkable impact on cancer s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de99fb8c9b00658a7643aa42bdc777e2
https://doi.org/10.1158/1538-7445.am2023-3456
https://doi.org/10.1158/1538-7445.am2023-3456
Autor:
Carmen Pin, Teresa Collins, Aaron Smith, S.Y. Amy Cheung, Lenka Oplustil O'Connor, James W.T. Yates, Duncan I. Jodrell, Jerome T. Mettetal, Chiara Fornari
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 858-868 (2019)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Haematological toxicity associated with cancer therapeutics is monitored by changes in blood cell count, and their primary effect is on proliferative progenitors in the bone marrow. Using observations in rat bone marrow and blood, we characterize a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::356e406c6e6461e115ee87ba49953cd9
https://doaj.org/article/5848ecf4800c4426a41a4c13b85eb890
https://doaj.org/article/5848ecf4800c4426a41a4c13b85eb890
Autor:
Mira Pavkovic, Anders B. Dohlman, Harish Shankaran, Vidya Chandrasekaran, Petar Todorov, Susanne Ramm, Maria Beatriz Monteiro, William W. Chen, Jeremy L. Muhlich, Jerome T. Mettetal, Vishal S. Vaidya
Publikováno v:
Toxicol Sci
The failure to predict kidney toxicity of new chemical entities early in the development process before they reach humans remains a critical issue. Here, we used primary human kidney cells and applied a systems biology approach that combines multidim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85594c069cb1a3200895ee2447118ca4
https://doi.org/10.1093/toxsci/kfz021
https://doi.org/10.1093/toxsci/kfz021
Autor:
Mayankbhai Patel, Santhosh Palani, Arijit Chakravarty, Johnny Yang, Wen Chyi Shyu, Jerome T Mettetal
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e109892 (2014)
Toxicity often limits the utility of oncology drugs, and optimization of dose schedule represents one option for mitigation of this toxicity. Here we explore the schedule-dependency of neutropenia, a common dose-limiting toxicity. To this end, we ana
Externí odkaz:
https://doaj.org/article/e467ffe512984529900d7eebfdaf78a1
Autor:
Andrew X. Chen, Arijit Chakravarty, Christopher J. Zopf, Wen Chyi Shyu, Joseph B. Bolen, Jerome T. Mettetal, Santhosh Palani
BackgroundThe effectiveness of many targeted therapies is limited by toxicity and the rise of drug resistance. A growing appreciation of the inherent redundancies of cancer signaling has led to a rise in the number of combination therapies under deve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0eb07124c0dce12d7ec53255c1334c5
https://doi.org/10.1101/2020.07.01.159657
https://doi.org/10.1101/2020.07.01.159657
Autor:
Samar Mahmoud, Avid M. Afzal, Amy Pointon, Nigel Greene, Fredrik Svensson, James Harvey, Andreas Bender, Jerome T. Mettetal, Ines Smit, Richard V. Williams, Kathryn A. Giblin, Azedine Zoufir, Peter Clements
Publikováno v:
Chemical Research in Toxicology. 31:1119-1127
Adverse events resulting from drug therapy can be a cause of drug withdrawal, reduced and or restricted clinical use, as well as a major economic burden for society. To increase the safety of new drugs, there is a need to better understand the mechan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::468ece67d4a40c03df67d959acb10c22
https://doi.org/10.1021/acs.chemrestox.8b00159
https://doi.org/10.1021/acs.chemrestox.8b00159